This page shows the latest UK biotech news and features for those working in and with pharma, biotech and healthcare.
UK biotech company Synairgen has treated the first patient in a phase 3 trial evaluating its potential COVID-19 treatment SNG001. ... We believe this trial presents an opportunity for a significant UK scientific breakthrough and, if given the right
This includes a deal announced last week with Surface Oncology for access to the biotech’s lead preclinical oncology asset. ... In addition, the British pharma company announced that it will co-lead series A investment and enter a collaboration deal on
UK biotech had initially been testing drug for COPD and asthma. ... Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing.
UK biotech says data is encouraging for separate trial programme in COVID-19. ... UK-based biotech Synairgen has revealed positive data for its inhaled drug SNG001 in chronic obstructive pulmonary disease (COPD) patients, results which the company says
The UK has also already agreed a deal with AstraZeneca to aid the research, development and manufacture of the vaccine it is developing with Oxford University. ... As part of that deal, AstraZeneca will manufacture 100 million doses of the vaccine for
The preliminary positive results are good news for the Southampton, UK-based biotech company, and come only four months after Synairgen announced the Medicines and Healthcare products Regulatory Agency (MHRA) and ... The double-blind, placebo-controlled
More from news
Approximately 27 fully matching, plus 164 partially matching documents found.
Creating a new biotech affiliate and seeking marketing authorisation for a new drug in the UK during a pandemic. ... With three COVID-19 vaccines approved for use in the UK at the time of publication, positive NICE recommendations for medicines like
We tend to experience the same challenges that all small biotech companies do – how do we ensure our therapies have the best chance of making it through to registration against a ... companies. However, it remains to be seen what effects Brexit may
Healx is based in Cambridge, UK, a key European biotech hub, and was founded in 2014 by Dr Tim Guilliams, a biochemical engineer and founder of the Cambridge Rare Disease Network, ... Why will the company make it in the high-risk, highly competitive
Why will Microbiotica make it in the high-risk, highly competitive biotech field? ... Of greater concern is the university sector – the UK biotech sector is what it is because of the increasing excellence of the university sector over the last 20 years.
Richard Mason (pictured above) is a veteran of the UK biotech industry, including a spell as CEO of company XO1 set up by venture capital investors Index Ventures (now Medicxi) in ... In the early days of UK biotech, this often led to major upfront
More from intelligence
Approximately 1 fully matching, plus 19 partially matching documents found.
New CMO to oversee development of lead candidate. UK biotech F-star has appointed Louis Kayitalire, MD, as its new Chief Medical Officer (CMO), wooing him from a senior role in ... F-star says this newly created management position will be crucial
Latest movers in pharma and biotech. Immunocore names new CEO. Bahija Jallal, Immunocore's next CEO. ... Immunotherapy-focused UK biotech company Immunocore has unveiled Bahija Jallal as its new chief executive and director of the board.
Lisa Anson joins the UK biotech as its CEO. Drug discovery and development group Redx Pharma has appointed its new chief executive officer in the form of Lisa Anson. ... substantial biotech company built upon an innovative science base, selectively
Dr Andrew Saunders joins the UK biotech from Lytix Biopharma. Drug discovery and development group Redx Pharma has appointed Dr Andrew Saunders as its chief medical officer (CMO), a role that ... He joins the UK biotech from Lytix Biopharma, a Norweigan
Dr Robert Lutz and Dr Jon Roffey join the UK biotech. ... Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.
More from appointments
Approximately 2 fully matching, plus 27 partially matching documents found.
Shula began working in medical communications in the USA following a successful research career in academia and the biotech industry in the UK, Germany and the USA. ... Coming back to the UK after 13 happy and successful years in America has given me the
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...